The PRIMA system is a subretinal implant designed to restore central vision in GA patients by replacing failed photoreceptors ...

CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely vision-impaired and blind patients, a randomized clinical trial showed. After ...

NEW YORK CITY -- A form of light therapy led to durable improvement in visual acuity for patients with dry age-related macular degeneration, according to interim results from an ongoing randomized ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...

Please provide your email address to receive an email when new articles are posted on . MCO-010, a mutation-agnostic gene therapy, demonstrated vision improvement in retinitis pigmentosa. Nanoscope ...

SEATTLE--(BUSINESS WIRE)--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data from its LIGHTSITE III, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Lumevoq demonstrated continued vision improvement in ...

Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...

Apple will soon release the first major software update for the Vision Pro, and the new version of visionOS will bring improvements not only to Personas, but also to the EyeSight feature. Personas and ...

An Iowa company has been ordered to halt sales of a product it claimed allowed for improvement in vision without surgery and to pay $200,000 in restitution to consumers, the state attorney general has ...